Breath-actuated Pressurized Inhaler Market Size, Share, and COVID-19 Impact Analysis, By Type (Dry Powder Inhaler and Breath Actuated Aerosol Inhaler), By Dose (Single Dose and Multiple Dose), By Indication (Asthma, Chronic Obstructive Pulmonary Disease, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Breath-actuated pressurized inhalers are devices that deliver medications directly to the lungs. These are used in conjunction with pressurized metered dose inhalers, which automatically trigger the inhaler spray when the patient is breathing in. This mechanism greatly reduces patient coordination errors and improves the compliance of patients with COPD and asthma.

The advantages of breath-actuated pressurized inhalers, such as improved deposition of drugs in the lungs as compared to the pressurized metered-dose inhaler (pMDI), and its ability to get actuated at low inspiratory flow rates, make it the most preferred choice for the treatment of asthma and COPD among physicians. To meet this growing demand for actuated pressurized inhalers, many of the key players are focusing on introducing new products, which is contributing to the market growth. For instance, in September 2020, Teva Pharmaceutical Industries Ltd. launched AirDuo Digihaler and ArmonAir Digihaler, the first digital, breath-actuated inhalers for patients with asthma.

Moreover, the growing prevalence of asthma and chronic obstructive pulmonary disease majorly contributes to the growing demand for breath-actuated pressurized inhalers. Based on statistics published by the National Heart, Lung, and Blood Institute in March 2022, asthma impacted 25.0 million people, among which more than 5.0 million were children. The statistics also stated that there were 16.0 million people afflicted with chronic obstructive pulmonary disorder in the U.S.

An increasing in investment by pharmaceutical industry participants for the development of new drugs and device combinations for the treatment of respiratory diseases is anticipated to drive the growth of the market. In addition, diversification in inhaler technologies, along with a surge in demand for more efficiently designed inhalers, augments product demand.

Impact of COVID-19 on the Global Breath-actuated Pressurized Inhaler Market

The COVID-19 pandemic had a minimal impact on the demand for breath-actuated pressurized inhalers. The market growth was impacted due to the reallocation of healthcare resources and fewer patients seeking treatment at hospitals during the pandemic. Moreover, the imposition of lockdowns in several countries disrupted the supply chain and impacted the sales of inhalers in the market. For instance, in FY 2020, AptarGroup, Inc. demonstrated a 2.0%  increase in the sales of their drug delivery systems for central nervous system and asthma treatments.

However, the resumption of post-pandemic surgeries and regular visits of patients to the hospitals led to a considerable demand for these devices and helped the steady growth of the market. For instance, in FY 2022, the allergic rhinitis and asthma treatment devices of AptarGroup, Inc. demonstrated an increase in sales of 11.0% compared to FY 2021.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Asthma and COPD, by Key Countries, 2022
• Technological Advancements in Breath-actuated Pressurized Inhalers
• Key Industry Developments – Partnerships, Mergers and New Product Launches
• Impact of COVID-19 on the Market

Analysis By Dose

Based on dose, the market is segmented into single dose and multiple dose.

The single dose segment is projected to grow at a significant CAGR over the study period. Significant improvement demonstrated by the single dose inhalers in the treatment of severe lung infection contributes to its growing adoption. Moreover, the convenience and low cost associated with these inhalers also drive the segment growth.

• For instance, in September 2020, GSK plc. and Innoviva, Inc. received approval from the U.S. FDA to use Trelegy Ellipta for the treatment of asthmatic patients aged 18 years and above. This approval extended the use of Trelegy Ellipta in the market.   

Regional Analysis

To gain extensive insights into the market, Download for Customization

North America is anticipated to lead the global breath-actuated pressurized inhaler market with a significant revenue share and is expected to flourish prominently during the analysis period. The region's significant growth is mainly attributed to the increasing prevalence of asthma and chronic obstructive pulmonary diseases in the region. Moreover, rising collaborations among key breath-actuated pressurized inhaler companies to introduce advanced products in North America and the growing participation of manufacturers in international conferences for the acquisition of new customers are further propelling the regional growth.

• In April 2022, Aptar Group Inc., one of the leading players in drug delivery products, organized a Respiratory Drug Delivery (RDD) conference series in Orlando, Florida. The event aimed to acquire a new customer base by showcasing and advertising their product portfolio at the conference.  

Key Players Covered:

The report includes the profiles of key players such as Cipla, AptarGroup, Inc., Teva Respiratory, LLC., GLENMARK PHARMACEUTICALS LTD., Novartis AG, GSK plc., and others.

Key Industry Developments

• In October 2022, AeroRx Therapeutics collaborated with HCmed Innovations to develop new therapeutic combinations of bronchodilators. The partnership was aimed at delivering the new combination through a breath-actuated mesh nebulizer platform called AdheResp.
• In February 2022, Aptar Pharma, a division of Aptar Group Inc., launched HeroTracker Sense, a next-generation metered-dose inhaler (MDI) designed to address patient inhalation technique and adherence.
• In February 2022, AstraZeneca collaborated with Honeywell for the development and commercialization of next-generation respiratory inhalers using the HFO-1234ze propellant.